Amgen's D-mab: The New EPO
D-mab is the new EPO. At least, that's what Amgen is hoping as it awaits FDA approval for its next growth engine, denosumab (D-mab). Assuming the drug gets to market--and Amgen is very confident it will--the drug's success will depend largely on pricing.
You may also be interested in...
The European Commission has finally granted a marketing authorization for Amgen's bone loss therapy, Prolia (denosumab), five months after CHMP issued a positive opinion
Amgen and GlaxoSmithKline will assume marketing responsibilities in Europe for osteoporosis, and Amgen will market it for oncology.
As European payers get more demanding, pharmaceutical commercial strategies are evolving even faster than in the U.S.